<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05793697</url>
  </required_header>
  <id_info>
    <org_study_id>different scores in AECOPD</org_study_id>
    <nct_id>NCT05793697</nct_id>
  </id_info>
  <brief_title>Assessment Of Different Scores In Predicting Outcome In AECOPD Patients In Emergency Department</brief_title>
  <official_title>Assessment Of Different Scores In Predicting Outcome In Acute Exacerbation Of Chronic Obstructive Pulmonary Disease Patients In Emergency Department</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      evaluate the value of different scores in predicting hospital mortality and Need for MV In&#xD;
      patients presented to ED with AECOPD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic obstructive pulmonary disease (COPD) is one of the top three causes of death&#xD;
      worldwide, and 90% of deaths occur in low- and middle-income countries.&#xD;
&#xD;
      Acute exacerbation of chronic obstructive pulmonary disease(AECOPD) is defined as an acute&#xD;
      change in patient's dyspnea, cough, or sputum beyond normal variability that is sufficient to&#xD;
      warrant a change in therapy. AECOPD has a negative effect on the quality of life, admission&#xD;
      and readmission rates, and disease progression.&#xD;
&#xD;
      For these reasons, appropriate management of acute exacerbations is recommended by national&#xD;
      and international organizations.&#xD;
&#xD;
      Identifying high-risk dying patients on hospital admission helps in triaging them to the&#xD;
      required level of care.&#xD;
&#xD;
      The use of early warning scores in follow-up is recommended for the early detection of&#xD;
      critically ill patients and the prediction of clinical deterioration. CURB65, BAP65, qSOFA ,&#xD;
      DECAF and NEWS, which mainly involve mental status, respiratory rate, oxygen saturations,&#xD;
      pulse, blood pressure, age, BUN level, etc., can be used to predict AECOPD-associated&#xD;
      mortality in ED given the simple structure and data availability.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 3, 2023</start_date>
  <completion_date type="Anticipated">December 3, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 3, 2024</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Crossover</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <target_duration>1 Day</target_duration>
  <primary_outcome>
    <measure>Evaluate the value of different scores in predicting hospital mortality</measure>
    <time_frame>one year</time_frame>
    <description>Assessment Of Different Scores In Predicting Outcome In Acute Exacerbation Of Chronic Obstructive Pulmonary Disease Patients In Emergency Department as DECAF(dyspnea grade V according to eMRCD,esinopenia&lt;0.05x10*9/L,consolidation,acidemia&lt;7.30,atrial fibrillation)&#xD;
1=mild,2_3=moderate,4_5=severe can be used to predict AECOPD-associated mortality in ED given the simple structure and data availability.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Value of these scores in predicting need for MV.</measure>
    <time_frame>one year</time_frame>
    <description>Value of these scores in predicting need for MV in AECOPD patient in ER</description>
  </secondary_outcome>
  <enrollment type="Anticipated">139</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <eligibility>
    <study_pop>
      <textblock>
        All patient presented to ED with acute exacerbation of COPD no gender discrimination from&#xD;
        18 years to unlimit age&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All patient presented to ED with acute exacerbation of COPD.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient presented with acute insult affecting other system.&#xD;
&#xD;
          -  Patient transferred to other centers.&#xD;
&#xD;
          -  Inadequate data.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>reham mo abdelmonem, MD</last_name>
    <role>Study Director</role>
    <affiliation>Assiut Uneversity</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>mohamed mo saleh, bachelor</last_name>
    <phone>01128534859</phone>
    <email>drmohamed33333@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>maha mo sayed, MD</last_name>
    <phone>01009656205</phone>
    <email>mahaelkholy@yahoo.com</email>
  </overall_contact_backup>
  <reference>
    <citation>Redfern OC, Smith GB, Prytherch DR, Meredith P, Inada-Kim M, Schmidt PE. A Comparison of the Quick Sequential (Sepsis-Related) Organ Failure Assessment Score and the National Early Warning Score in Non-ICU Patients With/Without Infection. Crit Care Med. 2018 Dec;46(12):1923-1933. doi: 10.1097/CCM.0000000000003359.</citation>
    <PMID>30130262</PMID>
  </reference>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>November 23, 2022</study_first_submitted>
  <study_first_submitted_qc>March 30, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">March 31, 2023</study_first_posted>
  <last_update_submitted>March 30, 2023</last_update_submitted>
  <last_update_submitted_qc>March 30, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Mohammed Mostafa Saleh Hussein</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Emergencies</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>sharing the result of the study after completion</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

